Login to Your Account

Financings NEWS

DUBLIN – Nextech Invest Ltd. missed the $100 million target it set for its Oncology Fund IV, closing with $64 million in the pot – enough to continue its focus on investing in high-quality firms focused on cancer.

LONDON – Precision Ocular Ltd. closed a £15.5 million (US$20.4 million) series A funding that will enable it to take the first of new generation of low-dose, slow-release retinal drugs from preclinical research and into the clinic.

In another promising sign for the gene therapy space, shares of Audentes Therapeutics Inc. received an encouraging welcome on Wall Street Wednesday after the firm priced a $75 million IPO, offering 5 million shares at $15 each, the midpoint of its proposed range.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: